期刊文献+

系统性红斑狼疮患者血清补体H因子水平及其意义 被引量:3

下载PDF
导出
摘要 目的:通过检测系统性红斑狼疮(SLE)患者血清补体因子H(CFH)的表达水平,探讨其水平变化与SLE患者其他实验室检测指标关系及其在SLE发病中的作用。方法:选取符合1982年美国风湿病学会制定的SLE诊断标准的37例SLE患者,另选30例健康对照者,采取酶联免疫吸附法(ELISA)检测SLE组及对照组血清中的CFH的水平,同时检测临床相关指标,分析CFH在各组患者血中的变化及其与临床各指标的相关性。结果:SLE患者血清CFH水平为(332.96±135.27)μg/L,低于正常对照组水平[(414.81±72.79)μg/L,P<0.05]。SLE血清CFH水平与补体C3呈明显正相关(r=0.518,P<0.001),与ds-DNA,尿微量白蛋白,SLEDAI评分呈负相关(r=-0.425,P<0.05;r=-0.472,P<0.05;r=-0.369,P<0.05)。结论:CFH的减少可能参与SLE的发病过程,特别与SLE造成肾脏损伤有关,是导致SLE患者低补体血症的因素之一,在一定程度上可反映疾病活动程度。
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2009年第12期1175-1176,1178,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 辽宁省科学技术计划项目(2007225013)
  • 相关文献

参考文献9

  • 1Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulo nephritis: report and genetic analysis of 16cases[J]. J Am Soc Nephrol, 2004, 15(3) : 787-795.
  • 2王海燕.肾脏病学[M]:2版[M].北京:人民卫生出版社,1997.999-1000.
  • 3Arason GJ, Steinsson K, Kolka R , et al. Patients with systemic lupus erythematosus are deficient in complement-dependent prevention of immune precipitation[ J ]. Rheumatology (Oxford), 2004, 43 (6) : 783 - 789.
  • 4Arora V, Verma J , Dutta R, et al. Reduced complement receptor 1 (CR1, CD35 ) transcription in systemic lupus erythematosus [J]. Mol Immunol, 2004, 41 (4): 449-456.
  • 5Lovgren T, Eloranta ML, Bave U, et al. Induction of interferon-production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG[J]. Arthritis Rheum, 2004, 50(6) : 1861 -1872.
  • 6毛立群,郭小芹,阎燕华.补体在系统性红斑狼疮中的作用[J].国外医学(内科学分册),2006,33(4):157-159. 被引量:5
  • 7Okiranta TS, Solomon A, Pangburn MK, et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H[J]. J Immunol, 1999, 163(8) : 4590 -4596.
  • 8李文根,庄俊汉,叶志中.系统性红斑狼疮早发动脉粥样硬化的研究进展[J].现代生物医学进展,2008,8(5):986-989. 被引量:3
  • 9Fujinami T, Hirata H, Hayano J , et al. Coronary risk factors in angiographieally defined patients with chest pain[J]. Jpn J Med, 1990,29(5): 462 -468.

二级参考文献41

  • 1Berkel AI, Birben E, Oner C, et al. [J]. Immunobiology, 2000,201 (3-4) :347-355.
  • 2Lipsker DM, Schreckenberg-Gilliot C, Uring-Lambert B, etal. [J]. Arch Dermatol,2000,136(12):1508-1514.
  • 3Anthony PM, Marina B, Mark JW. [J]. Annu Immuno1,2004,22:431-439.
  • 4Racila DM, Sontheimer C J, Sheffield A, et al.[J]. Lupus,2003,12(2) :124-132.
  • 5Yang Y, Chung EK, Zhou B, et al. [J]. Curr Dir Autoimmun,2004,7:98-132.
  • 6Ho A, Barr SG, Magder LS, et al. [J]. Arthritis Rheum,2001,44(10) :2350-2357.
  • 7Oelzner P, Deliyska B, Funfstuck R, et al. [J].Clin Rheumato1,2003,22 ( 4-5 ) :271-278.
  • 8Baumann I, Kolowos W, Voll RE, et al. [J].Arthritis Rheum ,2002,46( 1 ) :191-201.
  • 9Bengtsson AA, Sturfeh G, Gullstrand B, et al.[J]. Clin Exp Immunol,2004,135(3) :535-543.
  • 10Licht R, Dieker JW, Jacobs CW, et al. [J].J Autoimmun ,2004,22 ( 2 ): 139-145.

共引文献14

同被引文献20

  • 1汪珍.尿微量蛋白及补体检测对系统性红斑狼疮早期肾病变的诊断价值[J].浙江中医药大学学报,2010,34(3):319-320. 被引量:2
  • 2De Gaudio AR,Adembri C, Grechi S, et al. Mieroalbuminuria as an early index of impairment of glomerular permeability in postoperative septic patients[ J]. Intensive Care Med,2000,26(9): 1364-1368.
  • 3Thorevska N, Sabahi R, Upadya A, et al. Micmalbuminuria in critically ill medical patients : prevalence, predictom, and prognostic significancc [ J]. Crit Care Med,2003,31 (4) : 1075 - 1081.
  • 4Mac Kinnon KL, Molnar Z, Lowe D, et al. Use of microalbuminuria as predictor of outcome in critically ill patients[ J]. Br J Anaesth ,2000, 84(2) : 239 - 241.
  • 5Gosling P. Critical illness: a view from the kidney [ J ]. Crit Care Med,2006,34(6) : 1852 - 1853.
  • 6李光韬,吕继成,张宏,王素霞,邹万忠.腰痛、血尿、蛋白尿伴紫癜[J].中国医刊,2007,42(9):71-73. 被引量:2
  • 7郑文军,林有坤,刘京平.系统性红斑狼疮患者C3、C4水平与病情活动的关系[J].临床皮肤科杂志,2008,37(1):26-27. 被引量:6
  • 8Hochberg MC. Updating the American college of rheumatology reviesed criteria for the classification of SLE[J]. Arthritis Rheum, 1997,40(9) : 1725.
  • 9Skaggs BJ, Lourenco EV, Hahn BH. Oral administration of different forms of a tolerogenic peptide to define the preparations and doses that delay anti-DNA antibody production and nephritis and prolong survival in SLE-prone mice[J]. Lupus,2011,20(9) :912-920.
  • 10Doria A,Gatto M. Nephritogenenic-antinephritogenic antibody network in lupus glomerulonephritis[J]. Lupus, 2012,21 (14) : 1492-1496.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部